Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Inceptor Bio LLC

Headquarters: Morrisville, NC, United States of America
Year Founded: 2020
Status: Private
BioCentury | Jul 26, 2023
Finance

July 26 Quick Takes: Versant’s Nexo launches with $60M series A round

Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
BioCentury | May 9, 2023
Management Tracks

Laronde’s Cagnoni to head R&D at Incyte

Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
BioCentury | Mar 24, 2023
Product Development

Landscape of emerging T cell therapies in cancer

Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells
BioCentury | Jan 6, 2023
Emerging Company Profile

BioCentury’s 2022 class of emerging companies

A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Sep 10, 2022
Discovery & Translation

A suite of liquid biopsy approaches for cancer detection and more

BioCentury’s roundup of translational news
BioCentury | May 20, 2022
Product Development

Next-gen NK cell enhancements in the clinic

Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
BioCentury | May 20, 2022
Emerging Company Profile

Inceptor: building persistence of cancer cell therapies

Inceptor aims to address cell therapy’s challenges with $37M in series A funding, a trio of platforms and a new manufacturing facility
BioCentury | Jul 8, 2021
Product Development

July 7 Quick Takes: Moderna launches flu trial of mRNA vaccine; plus Quidel recall, NIH, WHO, Boehringer-Lilly, Novartis and more

Moderna Inc. (NASDAQ:MRNA) dosed the first participants in a Phase I/II trial of quadrivalent seasonal mRNA influenza vaccine mRNA-1010 that will help determine whether the manufacturing and efficacy
Items per page:
1 - 8 of 8